NasdaqGS:TECHLife Sciences
Bio-Techne (TECH): Do Steady Dividends Amid Soft Sales Reveal Its True Capital Allocation Priorities?
Bio-Techne Corporation reported its fiscal third-quarter 2026 results in early May, with net sales of US$311.42 million, a 2% year-over-year decline, while net income rose to US$51.05 million and diluted EPS from continuing operations increased to US$0.32.
Alongside softer demand from emerging biotech customers and shipment timing issues that weighed on revenue, Bio-Techne’s profitability improved and the Board affirmed a quarterly cash dividend of US$0.08 per share, highlighting an ongoing...